

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

The rejection of claims 1-88 and 137-148 under 35 U.S.C. § 112 (first para.) for lack of enablement is respectfully traversed in view of the above amendments.

The rejection of claims 58-60 under 35 U.S.C. § 112 (first para.) for lack of enablement is respectfully traversed in view of the above amendments.

The rejection of claims 1-88 and 138-147 under 35 U.S.C. § 112 (second para.) for indefiniteness is respectfully traversed in view of the above amendments.

As to claim 1, applicants submit that the above amendments are fully supported by the disclosure of the present application. See Figures 3-10, 13 and pages 15-19 and 24-25, which depict and describe oligonucleotide probes with distinct target-specific and addressable array-specific portions, and page 13, lines 35-38, which teach that oligonucleotide probes can be formed from nucleotides.

In view of all the foregoing, it is submitted that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: August 23, 1999

Michael L. Goldman
Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1304
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8 (a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. on the date below.	
8/23/99 Date	<u>Wendy L. Harrold</u> Wendy L. Harrold